Menu

Federal Ban Lifted on Studying Most Dangerous Pathogens

Only a few labs will earn funding for such “gain-of-function” research on SARS, MERS, and other deadly diseases.

Dec 20, 2017
Kerry Grens

WIKIMEDIA, THE US FOOD AND DRUG ADMINISTRATIONAs of Tuesday (December 19), the US government has ended its moratorium on funding “gain-of-function” research on deadly pathogens. These studies allow for the manipulation of potentially pandemic-causing viruses.

According to The Washington Post, National Institutes of Health Director Francis Collins told reporters that the government has developed a new, stringent policy outlining the justifications necessary for such risky investigations to receive money. “This kind of research can only be conducted in a very few places that have the highest level of containment,” Collins said.

The ban emerged in 2014 after a series of concerning events. In 2012, researchers had developed an influenza virus that ferrets could catch through the air. Then in 2014, biosafety mishaps shook up federal agencies—one involved staff being exposed to anthrax, another with forgotten vials of smallpox that were discovered in a storage facility.

The ban’s end “is very good news for laboratories interested in understanding the threat of natural pathogens to the human population,” James Paulson, a researcher at The Scripps Research Institute, tells NPR.

But the scientific community is not in complete agreement that gain-of-function studies are warranted. Marc Lipsitch, an epidemiologist at the Harvard T.H. Chan School of Public Health tells Nature that such studies “have done almost nothing to improve our preparedness for pandemics—yet they risked creating an accidental pandemic.” 

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.

Thermo Fisher Scientific: Freezers for Biological Samples

Thermo Fisher Scientific: Freezers for Biological Samples

Fluctuations in temperature can reduce the efficacy, decompose, or shorten the shelf life of biologics. Therefore, it is important to store biologics at the right temperature using standardized protocols.